Loading
A 37-expert consensus supported selected circulating tumour cell uses in metastatic breast and prostate cancer but said most other uses remain investigational. It identified CellSearch as the only platform with high-level clinical-use evidence and did not evaluate or endorse RGCC tests.
Eleven experts designed a structured survey that 37 international specialists completed. The panel reached consensus on selected prognostic and monitoring uses of circulating tumour cells in metastatic breast and prostate cancer and on AR-V7 testing for treatment selection in metastatic castration-resistant prostate cancer. It judged early-stage use and most other tumour settings investigational.
The panel stated that CellSearch was the only platform with high-level evidence for clinical use. It called molecular and phenotypic treatment guidance promising but in need of standardised workflows and robust prospective data. This is context for the CTC field, not validation of RGCC's capture, culture, expression or drug-sensitivity methods.
Evidence for one validated circulating tumour cell platform or one defined biomarker cannot be transferred automatically to every CTC assay. A branded test needs its own analytical validation, clinical validation and evidence that acting on the result helps patients.
Shares RGCC International, Circulating tumour cell capture, Liquid biopsy (ctDNA), Colorectal cancer.
Shares CellSearch circulating tumour cell count, Circulating tumour cell capture, Liquid biopsy (ctDNA), Breast cancer (all types).
Shares RGCC International, Circulating tumour cell capture, Liquid biopsy (ctDNA).
Shares Circulating tumour cell capture, Liquid biopsy (ctDNA), Breast cancer (all types).
Shares CellSearch circulating tumour cell count, Circulating tumour cell capture, Liquid biopsy (ctDNA), Breast cancer (all types).
Shares Circulating tumour cell capture, Liquid biopsy (ctDNA), Breast cancer (all types), Prostate cancer.
Shares RGCC International, Colorectal cancer.
Shares Circulating tumour cell capture, Liquid biopsy (ctDNA).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/